Skip to content
Screener

Innoviva, Inc. INVA Deferred Tax Assets

Deferred Tax Assets at other companies

Pfizer logo
PfizerPFE
-$12M-101%
Merck & Co. logo
Merck & Co.MRK
$1.43B+0.4%
AbbVie logo
AbbVieABBV
$137M-94.7%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$9.28M+51.4%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$21.65M-32.8%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$243.28M

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemJune 30, 2026 / (Unaudited)December 31, 2025 / *
Total current liabilities47,06449,696
Long-term debt, net of discount and issuance costs258,454257,731
Other long-term liabilities67,27666,091
Deferred tax liabilities, net36,73931,793
Income tax payable, long-term59,93257,013
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s deferred tax assets?
Innoviva, Inc. (INVA) reported deferred tax assets of $36.74M in Q2 2026.
How has Innoviva, Inc.'s deferred tax assets changed year-over-year?
Innoviva, Inc.'s deferred tax assets increased by 184.1% year-over-year, from $12.93M to $36.74M.
What is the long-term trend for Innoviva, Inc.'s deferred tax assets?
Over 5 years (2020 to 2025), Innoviva, Inc.'s deferred tax assets has grown at a -19.5% compound annual growth rate (CAGR), from $93.76M to $31.79M.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.

Ask your AI about Innoviva, Inc.'s deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude